|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1201 Maryland Avenue SW |
Address2 | Suite 900 |
| City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
3. Principal place of business (if different than line 2)
| City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 6245-12
|
||||||||
|
6. House ID# 325050000
|
||||||||
| TYPE OF REPORT | 8. Year | 2011 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Brent DelMonte, Vice President for Federal Government Relations |
Date | 10/20/2011 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AGR
16. Specific lobbying issues
Biomass Crop Assistance Program (BCAP) Funding
H.R. 2112: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2012
USDA/APHIS Agricultural Biotechnology Regulations
Coexistence of Production Systems
EPA Regulations on Agricultural Biotechnology
EPA Notice on PIP Data Requirements
Reauthorization and Implementation of Pesticide Registration Improvement Act
Livestock Cloning/Product Labeling
Discussions with EU on Animal Cloning
Genetically Engineered (GE) Animals
H.R. 2112: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2012
Amendment to Restrict FDA Approval of GE Salmon
FDA Approval
Labeling
Export Registrations for Products with Expired Patents
U.S. Policy on International Science-Based Regulations
Codex Standards
TransPacific Partnership
Sanitary and Phytosanitary Issues
Foreign Agricultural Biotechnology Laws and Regulations
International Biotechnology Agreement
Discussions with EU on Animal Cloning
China Biotechnology Regulations
Low-Level Presence Foreign Government Polices
European Union Low-Level Presence Policy
EU Biotechnology Bilateral Discussions
Korea Biotechnology Regulations
APEC Agricultural Biotechnology Discussions
Regulatory Actions on Biological Pesticides
H.R. 872: Reducing Regulatory Burdens Act of 2011
Agricultural Biotechnology Regulatory Reform and Modernization
House Agriculture Subcommittee Hearings
Potential Regulation of New Genetic Modification Technologies
EU Workshop
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), U.S. Trade Representative (USTR), Environmental Protection Agency (EPA), Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ab |
Basu |
|
|
|
David |
Edwards |
|
|
|
Tracey |
LaTurner |
|
|
|
Dana |
O'Brien |
|
|
|
Matthew |
O'Mara |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
Livestock Cloning/Product Labeling
Discussions with EU on Animal Cloning
Genetically Engineered (GE) Animals
H.R. 2112: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2012
Amendment to Restrict FDA Approval of GE salmon
FDA Approval
Labeling
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ab |
Basu |
|
|
|
David |
Edwards |
|
|
|
Dana |
O'Brien |
|
|
|
Tracey |
LaTurner |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Funding for Biomass Crop Assistance Program (BCAP)
H.R. 2112: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2012
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
S.R. 1599: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for
FY 2012
Funding for FDA (Human Drug Review, Biologics, Food Safety, Critical Path, Reagan-Udall Foundation, Center for Veterinary Medicine, Scientific Infrastructure)
H.R. 2112: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act
for FY 2012
Funding for Bio-based Products
H.R. 2354: The Energy and Water Appropriations Act for FY 2012
H.R. 2219: Department of Defense Appropriations Act for FY 2012
Funding for Biofuels
H.R. 2354: The Energy and Water Appropriations Act for FY 2012
H.R. 2219: Department of Defense Appropriations Act for FY 2012
Funding for Centers for Disease Control and Prevention Vaccine Programs
S.R. 1599: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for
FY 2012
Funding for National Institutes of Health
Cures Acceleration Network
S.R. 1599: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for
FY 2012
Genetically Engineered (GE) Animals
H.R. 2112: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2012
Amendment to Restrict FDA Approval of GE Salmon
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), Centers For Disease Control & Prevention (CDC),
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Phyllis |
Arthur |
|
|
|
Ab |
Basu |
|
|
|
Matt |
Carr |
|
|
|
David |
Edwards |
|
|
|
Andrew |
Emmett |
|
|
|
Cartier |
Esham |
|
|
|
Tracey |
LaTurner |
|
|
|
Dana |
O'Brien |
|
|
|
Sara |
Radcliffe |
|
|
|
Sarah |
Thornton |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CAW
16. Specific lobbying issues
IP Rights for Environmental Technologies
U.S. Government Position for U.N. Convention on Climate Change Negotiations
Biofuels
Department of Defense Applications of Advanced Biofuels (Opposition to Section 526 Repeal)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Navy - Dept of, Energy - Dept of, Agriculture - Dept of (USDA), State - Dept of (DOS), Defense - Dept of (DOD)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dana |
O'Brien |
|
|
|
Matt |
Carr |
|
|
|
Sarah |
Thornton |
|
|
|
Roy |
Zwahlen |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Patent Reform
H.R. 1249: The Leahy-Smith America Invents Act of 2011
S. 23: The Patent Reform Act of 2011
Implementation of H.R. 1249: The America Invents Act of 2011
IP Rights for Environmental Technologies
U.S. Government Position for U.N. Convention on Climate Change Negotiations
Generic Drug Patent Settlements
Genetic Resource Patent Disclosure Requirement
World Intellectual Property Organization
Philippines
DNA Patenting and Licensing
Rep. Wasserman Schultz Amendment to H.R. 1249: The America Invents Act of 2011
Bayh-Dole Act/Tech Transfer
Bayh-Dole Act/Tech Transfer
Commercialization of Federally Funded Research Initiative
Domestic Manufacturing Requirement
Intellectual Property International Enforcement
TransPacific Partnership
Data and Intellectual Property Protections for Pharmaceuticals
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Patent & Trademark Office (PTO), State - Dept of (DOS), U.S. Trade Representative (USTR),
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Lila |
Feisee |
|
|
|
Hans |
Sauer |
|
|
|
Matthew |
Schumaker |
|
|
|
Anna |
Weinstein |
|
|
|
Melissa |
Bowie |
|
|
|
Tom |
DiLenge |
|
|
|
Jeanne |
Haggerty |
|
|
|
Sara |
Radcliffe |
|
|
|
Roy |
Zwahlen |
|
|
|
Charles |
Fritts |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
Livestock Cloning/Product Labeling
Discussions with EU on Animal Cloning
USDA/APHIS Agricultural Biotechnology Regulations
Coexistence of Production Systems
Genetically Engineered (GE) Animals
FDA Approval
Labeling
H.R. 2112: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2012
Amendment to Restrict FDA Approval of GE Salmon
Generic Drug Patent Settlements
Drug Safety and Review
S. 1584: Drug Safety and Accountability Act of 2011
Prescription Drug User Fee Act (PDUFA) Reauthorization
Regulatory Reforms for Innovative Products
Funding for FDA (Human Drug Review, Biologics, Food Safety, Critical Path, Reagan-Udall Foundation, Center for
Veterinary Medicine, Scientific Infrastructure)
H.R. 2112: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations
Act for FY 2012
Drug Shortages
H.R. 2245: Preserving Access to Life Saving Medicines Act of 2011
S. 296: Preserving Access to Life-Savings Medicines Act of 2011
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), U.S. Trade Representative (USTR), Office of Science & Technology Policy (OSTP), Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ab |
Basu |
|
|
|
David |
Edwards |
|
|
|
Andrew |
Emmett |
|
|
|
Anna |
Weinstein |
|
|
|
Sara |
Radcliffe |
|
|
|
Phyllis |
Arthur |
|
|
|
Sandi |
Dennis |
|
|
|
Dana |
O'Brien |
|
|
|
Melissa |
Bowie |
|
|
|
Tracey |
LaTurner |
|
|
|
Matthew |
Schumaker |
|
|
|
Brent |
Del Monte |
|
|
|
Cartier |
Esham |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
DiLenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENG
16. Specific lobbying issues
Renewable Fuels Standard
S.1564: The Renewable Fuel Parity Act of 2011
Biofuels
Economic Growth Impact/Potential of Advanced Biofuels
Department of Defense Applications of Advanced Biofuels (Opposition to Section 526 Repeal)
Investment Tax Credit Options
DOE Loan Guarantees and Grants under the Energy Policy Act of 2005 (Implementation and Funding)
Economic Growth Impact/Potential of Advanced Biofuels
Biofuels Production Tax Credit Modification for Algae-based Biofuels
Next Generation Incentives : Farm Bill Reauthorization
Biofuels Production Tax Credit Extension
Funding for Biofuels
H.R. 2354: The Energy and Water Appropriations Act for 2012
H.R. 2219: Department of Defense Appropriations Act for FY 2012
Bio-based Products
Expansion of DOE and USDA Loan Guarantee Programs
Next Generation Incentives: Farm Bill Reauthorization
USDA BioPreferred Program
Economic Growth Impact/Potential of Advanced Bio-based Products
Tax Credit
Funding for Bio-based Products
H.R. 2354: The Energy and Water Appropriations Act for 2012
H.R. 2219: Department of Defense Appropriations Act for FY 2012
Renewable Chemicals
Farm Bill Reauthorization: DOE Loan Guarantees
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, Energy - Dept of, Agriculture - Dept of (USDA), Defense - Dept of (DOD), Navy - Dept of, U.S. SENATE, Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matt |
Carr |
|
|
|
Dana |
O'Brien |
|
|
|
Tracey |
LaTurner |
|
|
|
Charles |
Fritts |
|
|
|
Rina |
Singh |
|
|
|
Sarah |
Thornton |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOO
16. Specific lobbying issues
Livestock Cloning/Product Labeling
Discussions with EU on Animal Cloning
Genetically Engineered (GE) Animals
H.R. 2112: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2012
Amendment to Restrict FDA Approval of GE Salmon
FDA Approval
Labeling
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, U.S. Trade Representative (USTR), Agriculture - Dept of (USDA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ab |
Basu |
|
|
|
David |
Edwards |
|
|
|
Dana |
O'Brien |
|
|
|
Tracey |
LaTurner |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FUE
16. Specific lobbying issues
Renewable Fuels Standard
S.1564: The Renewable Fuel Parity Act of 2011
Biofuels
Economic Growth Impact/Potential of Advanced Biofuels
Department of Defense Applications of Advanced Biofuels (Opposition to Section 526 Repeal)
Investment Tax Credit Options
DOE Loan Guarantees and Grants under the Energy Policy Act of 2005 (Implementation and Funding)
Economic Growth Impact/Potential of Advanced Biofuels
Biofuels Production Tax Credit Modification for Algae-based Biofuels
Next Generation Incentives : Farm Bill Reauthorization
Biofuels Production Tax Credit Extension
Funding for Biofuels
H.R. 2354: The Energy and Water Appropriations Act for 2012
H.R. 2219: Department of Defense Appropriations Act for FY 2012
Bio-based Products
Expansion of DOE and USDA Loan Guarantee Programs
Next Generation Incentives: Farm Bill Reauthorization
USDA BioPreferred Program
Economic Growth Impact/Potential of Advanced Bio-based Products
Tax Credit
Funding for Bio-based Products
H.R. 2354: The Energy and Water Appropriations Act for 2012
H.R. 2219: Department of Defense Appropriations Act for FY 2012
Renewable Chemicals
Farm Bill Reauthorization: DOE Loan Guarantees
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Energy - Dept of, Agriculture - Dept of (USDA), Defense - Dept of (DOD), Navy - Dept of, Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matt |
Carr |
|
|
|
Dana |
O'Brien |
|
|
|
Tracey |
LaTurner |
|
|
|
Charles |
Fritts |
|
|
|
Rina |
Singh |
|
|
|
Sarah |
Thornton |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Medicaid Rebates
Dual Eligibles
Generic Fill Incentives
Medicare Prescription Drug Coverage
Transfer of Certain Drugs from Part B to Part D
Implementation of H.R. 3590: (Senate) Patient Protection and Affordable Care Act
Biosimilars
Implementation of H.R. 3590:(Senate) Patient Protection and Affordable Care Act
Reimbursement Issues
Funding for National Institutes of Health
S.R. 1599: Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations for FY 2012
Funding for Centers for Disease Control and Prevention Vaccine Programs
S.R. 1599: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations
Act for FY 2012
Expansion of 340B Drug Pricing Program
Implementation of H.R. 3590: (Senate) Patient Protection and Affordable Care Act
Diagnostics and Personalized Medicine Regulation and Oversight
Therapeutic Discovery Project Tax Credit
Extension
Rare Pediatric & Tropical Disease Drug Development
Drug Safety and Review
S. 1584: Drug Safety and Accountability Act of 2011
Prescription Drug User Fee Act (PDUFA) Reauthorization
Regulatory Reforms for Innovative Products
Funding for FDA (Human Drug Review, Biologics, Food Safety, Critical Path, Reagan-Udall Foundation, Center for Veterinary Medicine, Scientific Infrastructure)
H.R. 2112: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act
for FY 2012
Independent Payment Advisory Board
Implementation of H.R. 3590: (Senate) Patient Protection and Affordable Care Act
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
S.R. 1599: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations
Act for FY 2012
Cures Acceleration Network
S. 1599: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations
Act for FY 2012
Biodefense Research, Development and Procurement (Non-Funding Issues)
Pandemic and All-Hazards Preparedness Act Reauthorization
HHS Countermeasures Review
Drug Shortages
H.R. 2245: Preserving Access to Life Saving Medicines Act of 2011
S. 296: Preserving Access to Life-Savings Medicines Act of 2011
TransPacific Partnership
Data and Intellectual Property Protection for Pharmaceuticals
Reimbursement for Innovative Products
Part B Physician-Administered Products
Medicare Policies and Regulation
17. House(s) of Congress and Federal agencies Check if None
Treasury - Dept of, U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Natl Institutes of Health (NIH), Food & Drug Administration (FDA), Office of Science & Technology Policy (OSTP), U.S. Trade Representative (USTR), Health & Human Services - Dept of (HHS), Centers For Disease Control & Prevention (CDC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shelly |
Mui-Lipnik |
|
|
|
Roy |
Zwahlen |
|
|
|
Sandi |
Dennis |
|
|
|
Andrew |
Emmett |
|
|
|
Matthew |
Schumaker |
|
|
|
Jeanne |
Haggerty |
|
|
|
Sara |
Radcliffe |
|
|
|
Phyllis |
Arthur |
|
|
|
Anna |
Weinstein |
|
|
|
Melissa |
Bowie |
|
|
|
Cartier |
Esham |
|
|
|
Lila |
Feisee |
|
|
|
Tom |
DiLenge |
|
|
|
Tracey |
LaTurner |
|
|
|
Laurel |
Todd |
|
|
|
Brent |
Del Monte |
|
|
|
Tooshar |
Swain |
|
|
|
Charles |
Fritts |
|
|
|
Alyson |
Pusey |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOM
16. Specific lobbying issues
Biodefense Research, Development and Procurement
HHS Countermeasures Review
Pandemic and All-Hazards Preparedness Act Reauthorization
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
S.R. 1599: Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations
for FY 2012
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Melissa |
Bowie |
|
|
|
Anna |
Weinstein |
|
|
|
Phyllis |
Arthur |
|
|
|
Tom |
DiLenge |
|
|
|
Tracey |
LaTurner |
|
|
|
Jeanne |
Haggerty |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Cures Acceleration Network
S.R. 1599: Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations for FY 2012
Funding for National Institutes of Health
S.R. 1599: Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations for FY 2012
Rare Pediatric & Tropical Disease Drug Development
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
S.R. 1599: Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations for FY 2012
Biodefense Research, Development and Procurement (Non-Funding Issues)
Pandemic and All-Hazards Preparedness Act Reauthorization
HHS Countermeasures Review
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Natl Institutes of Health (NIH), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matthew |
Schumaker |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tracey |
LaTurner |
|
|
|
Anna |
Weinstein |
|
|
|
Melissa |
Bowie |
|
|
|
Phyllis |
Arthur |
|
|
|
Cartier |
Esham |
|
|
|
Tom |
DiLenge |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicaid Rebates
Dual Eligibles
Medicare Prescription Drug Coverage
Transfer of Certain Drugs from Part B to Part D
Implementation of H.R. 3590: (Senate) Patient Protection and Affordable Care Act
Independent Payment Advisory Board
Implementation of H.R. 3590: (Senate) Patient Protection and Affordable Care Act
Reimbursement for Innovative Products
Part B Physician-Administered Products
Medicare Policies and Regulation
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE,
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matthew |
Schumaker |
|
|
|
Melissa |
Bowie |
|
|
|
Jeanne |
Haggerty |
|
|
|
Anna |
Weinstein |
|
|
|
Sara |
Radcliffe |
|
|
|
Laurel |
Todd |
|
|
|
Sandi |
Dennis |
|
|
|
Brent |
Del Monte |
|
|
|
Alyson |
Pusey |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SCI
16. Specific lobbying issues
Small Business Innovation and Research (SBIR) Program Reauthorization
HR 1425: Creating Jobs Through Small Business Innovation Act of 2011
S.493: SBIR/STTR Reauthorization Act of 2011
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE,
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cartier |
Esham |
|
|
|
Charles |
Fritts |
|
|
|
Alan |
Eisenberg |
|
|
|
Brent |
Del Monte |
|
|
|
. |
. |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SMB
16. Specific lobbying issues
Capital Formation Investment Incentives
Sarbanes Oxley Section 404 (b) Exemption
Small Company Job Growth and Regulatory Relief Act of 2011 (Discussion Draft)
Small Business Innovation and Research (SBIR) Program Reauthorization
HR 1425: Creating Jobs through Small Business Innovation Act of 2011
S.493: SBIR/STTR Reauthorization Act of 2011
Small Business Early-Stage Investment
Therapeutic Discovery Project Tax Credit
Extension
Expansion of Eligibility under SEC Regulation A
H.R. 1070: The Small Company Capital Formation Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Treasury - Dept of, Securities & Exchange Commission (SEC),
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cartier |
Esham |
|
|
|
Charles |
Fritts |
|
|
|
Alan |
Eisenberg |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Tooshar |
Swain |
|
|
|
Matthew |
Schumaker |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Bio-based Products
Tax Credit
Therapeutic Discovery Project Tax Credit
Extension
Biofuels
Investment Tax Credit Options
Biofuels Production Tax Credit Modification for Algae-based Biofuels
Biofuels Production Tax Credit Extension
Capital Formation Investment Incentives
Expansion of Eligibility under SEC Regulation A
H.R. 1070: The Small Company Capital Formation Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Treasury - Dept of
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matt |
Carr |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Dana |
O'Brien |
|
|
|
Matthew |
Schumaker |
|
|
|
Rina |
Singh |
|
|
|
Charles |
Fritts |
|
|
|
Tracey |
LaTurner |
|
|
|
Sarah |
Thornton |
|
|
|
Cartier |
Esham |
|
|
|
Tooshar |
Swain |
|
|
|
Alan |
Eisenberg |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Livestock Cloning/Product Labeling
Discussions with EU on Animal Cloning
Export Registrations for Products with Expired Patents
U.S. Policy on International Science-Based Regulations
Codex Standards
Intellectual Property International Enforcement
TransPacific Partnership
Sanitary and Phytosanitary Issues
Data and Intellectual Property for Pharmaceuticals
Foreign Agricultural Biotechnology Laws and Regulations
International Biotechnology Agreement
Discussions with EU on Animal Cloning
China Biotechnology Regulations
Low-Level Presence Foreign Government Policies
European Union Low Level Presence Policy
EU Biotechnology Bilateral Discussions
Korea Biotechnology Regulations
APEC Agricultural Biotechnology Discussions
Genetic Resource Patent Disclosure Requirement
World Intellectual Property Organization
Philippines
IP Rights for Environmental Technologies
U.S. Government Position for U.N. Convention on Climate Change Negotiations
Potential Regulation of New Genetic Modification Technologies
EU Workshop
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, U.S. Trade Representative (USTR), Agriculture - Dept of (USDA), State - Dept of (DOS), Commerce - Dept of (DOC), Patent & Trademark Office (PTO), Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Melissa |
Bowie |
|
|
|
David |
Edwards |
|
|
|
Matthew |
Schumaker |
|
|
|
Lila |
Feisee |
|
|
|
Tom |
DiLenge |
|
|
|
Jeanne |
Haggerty |
|
|
|
Roy |
Zwahlen |
|
|
|
Matthew |
O'Mara |
|
|
|
Dana |
O'Brien |
|
|
|
Brent |
Del Monte |
|
|
|
Sara |
Radcliffe |
|
|
|
Anna |
Weinstein |
|
|
|
Charles |
Fritts |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Medicaid Rebates
Dual Eligibles
Generic Fill Incentives
Medicare Prescription Drug Coverage
Transfer of Certain Drugs from Part B to Part D
Implementation of H.R. 3590: (Senate) Patient Protection and Affordable Care Act
Drug Shortages
H.R. 2245: Preserving Access to Life Saving Medicines Act of 2011
S. 296: Preserving Access to Life-Savings Medicines Act of 2011
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE,
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Andrew |
Emmett |
|
|
|
Matthew |
Schumaker |
|
|
|
Anna |
Weinstein |
|
|
|
Sandi |
Dennis |
|
|
|
Sara |
Radcliffe |
|
|
|
Jeanne |
Haggerty |
|
|
|
Brent |
Del Monte |
|
|
|
Melissa |
Bowie |
|
|
|
Alyson |
Pusey |
|
|
|
Laurel |
Todd |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address | |
||||||
| City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
| City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
5 |
|
||||||
| 2 |
|
6 |
|
||||||
| 3 |
|
7 |
|
||||||
| 4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address: BIO maintains a list of all of its members on its website at http://bio.org/membership/index.asp
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 3 | 5 |
| 2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 5 | 9 |
| 2 | 6 | 10 |
| 3 | 7 | 11 |
| 4 | 8 | 12 |